Tobacco Consumption Concerns With the Use of CYP1A2 Metabolized Antidepressants

Am J Psychiatry. 2015 Sep 1;172(9):909-10. doi: 10.1176/appi.ajp.2015.15010033.

Authors

Florence Gressier¹, Samuel Rotenberg¹, Abd El Kader Ait Tayeb¹, Romain Colle¹, Patrick Hardy¹, Laurent Becquemont¹, Céline Verstuyft¹, Emmanuelle Corruble¹

Affiliation

¹ From the Department of Psychiatry and the Department of Molecular Genetics, Pharmacogenetics, and Hormonology, Assistance Publique-Hôpitaux de Paris, and the French Institute of Health and Medical Research, Bicêtre University Hospital, Université Paris-Sud, Le Kremlin Bicêtre, France.

PMID: 26324305
DOI: 10.1176/appi.ajp.2015.15010033

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antidepressive Agents, Tricyclic / adverse effects
Antidepressive Agents, Tricyclic / metabolism
Antidepressive Agents, Tricyclic / therapeutic use*
Cytochrome P-450 CYP1A2 / drug effects*
Cytochrome P-450 CYP1A2 / genetics
Cytochrome P-450 CYP1A2 / metabolism
Depressive Disorder, Major / complications
Depressive Disorder, Major / drug therapy*
Female
Genotype
Heterozygote
Humans
Imipramine / adverse effects
Imipramine / metabolism
Imipramine / therapeutic use*
Middle Aged
Polymorphism, Single Nucleotide / genetics
Recurrence
Tobacco Use Disorder / complications*
Tobacco Use Disorder / genetics

Substances

Antidepressive Agents, Tricyclic
Cytochrome P-450 CYP1A2
Imipramine